3
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Plasma cell
1
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Genitourinary
1
Gastrointestinal
1
Classical hematology
1
Breast
1
Conditions
Multiple Myeloma
2
Lymphoma
2
Venous Thrombosis
1
Venous Thromboembolism
1
Vascular Diseases
1
Urogenital Neoplasms
1
Thromboembolism
1
Prostatic Neoplasms
1
Neoplasms
1
Myeloproliferative Disorders
1
Lymphoproliferative Disorders
1
Lymphatic Diseases
1
Lung Neoplasms
1
Leukemia
1
Intestinal Neoplasms
1
Hemostatic Disorders
1
Digestive System Neoplasms
1
Colorectal Neoplasms
1
Breast Neoplasms
1
Interventions
Cyclophosphamide
10
pembrolizumab
9
Therapeutics
8
Flow Cytometry
6
Radiotherapy
5
Gemcitabine
5
Blood Specimen Collection
5
Surveys and Questionnaires
4
Sirolimus
4
Psychiatric Rehabilitation
4
Peripheral Blood Stem Cell Transplantation
4
Paclitaxel
4
Nivolumab
4
Methods
4
Ipilimumab
4
Filgrastim
4
Exercise
4
Drug Therapy
4
Doxorubicin
4
Capecitabine
4
copanlisib
3
aldesleukin
3
Rituximab
3
Polymerase Chain Reaction
3
Immunologic Techniques
3
Immunoglobulin G
3
Immunoenzyme Techniques
3
Fluorodeoxyglucose F18
3
Early Intervention, Educational
3
Disulfides
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Breast Neoplasms
×
Tinzaparin
×
Lymphoid
×
Clear all
NCT03099031
2019-12-16
PREDICARE
LEO Pharma
Completed
420 enrolled